Leerink Partners Has Lowered Expectations for Medtronic (NYSE:MDT) Stock Price

Medtronic (NYSE:MDT) had its price objective dropped by investment analysts at Leerink Partners from $120.00 to $119.00 in a report issued on Wednesday,MarketScreener reports. The brokerage currently has an “outperform” rating on the medical technology company’s stock. Leerink Partners’ price target indicates a potential upside of 23.75% from the company’s current price.

Other research analysts also recently issued research reports about the company. Jefferies Financial Group reaffirmed a “hold” rating and issued a $110.00 price objective on shares of Medtronic in a research note on Wednesday, November 19th. Wells Fargo & Company began coverage on shares of Medtronic in a research report on Friday, January 30th. They issued an “overweight” rating and a $114.00 price target for the company. Robert W. Baird dropped their price target on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday. Morgan Stanley boosted their price objective on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Finally, The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the company a “neutral” rating in a report on Wednesday, November 19th. Sixteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $111.05.

Medtronic Stock Performance

MDT traded down $0.25 during trading on Wednesday, hitting $96.16. The stock had a trading volume of 713,776 shares, compared to its average volume of 8,479,095. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The company has a 50 day moving average price of $99.19 and a 200-day moving average price of $96.58. Medtronic has a one year low of $79.55 and a one year high of $106.33. The firm has a market cap of $123.28 billion, a price-to-earnings ratio of 25.92, a P/E/G ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts predict that Medtronic will post 5.46 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. AXQ Capital LP lifted its position in shares of Medtronic by 25.6% in the second quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after buying an additional 2,013 shares in the last quarter. UMB Bank n.a. grew its holdings in Medtronic by 65.8% during the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after buying an additional 54,898 shares in the last quarter. Applied Finance Capital Management LLC bought a new stake in Medtronic in the 3rd quarter worth approximately $1,308,000. Principal Financial Group Inc. increased its stake in Medtronic by 17.2% in the 3rd quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock worth $157,732,000 after acquiring an additional 242,910 shares during the last quarter. Finally, Willis Investment Counsel boosted its position in shares of Medtronic by 5.0% during the 3rd quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock valued at $38,274,000 after acquiring an additional 19,192 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat and reiterated guidance — Medtronic reported $9.02B revenue and $1.36 non‑GAAP EPS (above estimates) and reaffirmed FY26 EPS guidance, which supports near‑term visibility. PR Newswire: Medtronic Q3 Results
• Positive Sentiment: Cardio & diabetes momentum — Cardiovascular revenue up double digits with Cardiac Ablation Solutions up ~80% (U.S. up 137%); diabetes also showed mid‑single digit growth — key organic drivers for revenue upside. PR Newswire: Segment Growth
• Positive Sentiment: Regulatory/commercial catalysts — FDA clearances and first U.S. Hugo robotic‑assisted surgery performed at Cleveland Clinic (plus Infuse bone graft OK for TLIF and MiniMed Flex submission), which expand addressable markets. PR Newswire: Hugo first U.S. case
• Positive Sentiment: Analyst bullishness — TD Cowen reiterated a Buy with a $119 PT, and Needham kept a Buy at $120 (small PT trims), signaling continued analyst conviction behind the recovery thesis. TipRanks: TD Cowen reiterates Buy
• Neutral Sentiment: Technicals & positioning — Market commentary points to a bullish reversal pattern and heavy institutional accumulation; useful context for momentum traders but not a fundamental driver. MarketBeat: Textbook reversal
• Negative Sentiment: Price‑target cut / neutral rating from Baird — Robert W. Baird trimmed its PT to $100 and moved to Neutral, which could cap upside for some investors. Benzinga: Baird PT cut
• Negative Sentiment: Margin pressure & rising costs — Reports note profit fell on higher costs and tariff impacts; margin compression is a near‑term risk even as revenue grows. WSJ: Profit falls despite higher revenue

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).